Navigation Links
Cerimon Pharmaceuticals Names Matthew J. Meyer its General Counsel and Vice President of Business Development and Licensing

SOUTH SAN FRANCISCO, Calif., Jan. 4 /PRNewswire/ -- Cerimon Pharmaceuticals, Inc. announced today that Matthew J. Meyer has been named General Counsel, a newly established position, and Vice President of Business Development and Licensing. Mr. Meyer is a global life sciences executive and corporate attorney with broad experience with large pharmaceutical, medical device and early-stage companies in the US and Europe. In the business development role, he replaces Timothy J. McBride, who will be furthering his career in Europe. Mr. Meyer will report to Paul Sekhri, President and CEO, and will be responsible for managing the Company's efforts to identify and secure new strategic business opportunities and product acquisitions.

Mr. Meyer brings considerable experience to his new role in the areas of commercial law, business development, marketing and licensing. Before joining Cerimon, Mr. Meyer held senior management positions at Draeger Medical Systems, a global medical device company, most recently serving as Vice President and General Counsel. Prior to Draeger, Mr. Meyer held several positions of increasing responsibility at Novartis Pharma AG in Basel, Switzerland, including serving as Head of Global Marketing Channel Innovations. While at Novartis, he also coordinated and implemented strategic commercial, marketing, research and development initiatives for the Arthritis, Bone, GI and Urology (ABGU) marketing franchise. Previously, Mr. Meyer spent four years as Vice President, Global Business Development and Legal Affairs at Allscripts LLC and five years as a commercial attorney at Pfizer Inc. in New York.

Mr. Meyer graduated Cum Laude and Phi Beta Kappa with a Bachelor of Arts degree from Cornell University. He earned his Juris Doctor degree from Villanova University School of Law.

"Matt Meyer's proven track record as an incisive leader in business development in the life sciences sector will be a valuable asset to this Company," commented Mr. Sekhri. "We are extremely pleased to have Matt join us as a member of our senior management team and believe he will contribute greatly to our efforts of building a pipeline of products aligned with our corporate strategy."

About Cerimon Pharmaceuticals

Cerimon Pharmaceuticals, Inc., is a biopharmaceutical company dedicated to developing and commercializing therapeutic products for autoimmune diseases, inflammation, and pain. Cerimon believes these new treatment options will enable physicians specialized in treating these conditions to further improve the lives of their patients.

Cerimon currently has two drugs in development. Simulect(R) (basiliximab) entered a Phase IIb study for moderate-to-severe ulcerative colitis in the first quarter of 2007. Cerimon's topical patch formulation of diclofenac sodium completed a Phase I study in the fourth quarter of 2007. This study will rapidly be followed by two Phase II/III studies for the treatment of acute musculoskeletal pain.

The Company is well-financed, having closed a $70 million Series A financing in late 2005 with premier investors including MPM, Nomura Phase4 Ventures, and OrbiMed Advisors.

For more information on Cerimon, please visit the Company's website at

SOURCE Cerimon Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Cerimon Pharmaceuticals to Present at the 2007 BIO Investor Forum
2. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
3. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
7. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
8. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
9. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
10. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
11. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
Post Your Comments:
(Date:6/27/2016)... NC (PRWEB) , ... June 27, 2016 , ... ... mission to bring innovative medical technologies, services and solutions to the healthcare market. ... and implementation of various distribution, manufacturing, sales and marketing strategies that are necessary ...
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
(Date:6/23/2016)... SANTA MONICA, Calif. , June 23, 2016  The Prostate Cancer ... to pioneer increasingly precise treatments and faster cures for prostate cancer. Members of ... 77 institutions across 15 countries. Read More About the ... ... ...
Breaking Biology Technology:
(Date:5/12/2016)... 2016 , a brand of ... results from the Q1 wave of its quarterly wearables ... consumers, receptivity to a program where they would receive ... insurance company. "We were surprised to see ... Michael LaColla , CEO of Troubadour Research, "primarily because ...
(Date:4/28/2016)... 2016 First quarter 2016:   ... with the first quarter of 2015 The gross margin ... (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... unchanged, SEK 7,000-8,500 M. The operating margin for 2016 ...
(Date:4/15/2016)... , April 15, 2016  A new ... make more accurate underwriting decisions in a fraction ... timely, competitively priced and high-value life insurance policies ... screenings. With Force Diagnostics, rapid testing ... lifestyle data readings (blood pressure, weight, pulse, BMI, ...
Breaking Biology News(10 mins):